

# Detection of Carbapenemase-producing *Klebsiella pneumoniae* isolated from Environmental Sources in a Tertiary Health Institution in Nigeria.

**Iloduba Nnaemeka Aghanya** (✉ [aghanyailoduba@gmail.com](mailto:aghanyailoduba@gmail.com))

Nnamdi Azikiwe University <https://orcid.org/0000-0003-4481-4834>

**Comfort Nne Akujobi**

Nnamdi Azikiwe University, Faculty of Medicine

**Simon Nkpeh Ushie**

Nnamdi Azikiwe University

**Chika Florence Ubajaka**

Nnamdi Azikiwe University

**Ijeoma Maryrose Ajuba**

Nnamdi Azikiwe University Teaching Hospital

**Chibuike Jesse Ezeama**

Nnamdi Azikiwe University

**Nkechi Perpetua Maduekwe**

Nnamdi Azikiwe University Teaching Hospital

**Ngozichukwu Gertrude Uzoewulu**

Nnamdi Azikiwe University

**Chisom Godswill Chigbo**

Nnamdi Azikiwe University

---

## Research note

**Keywords:** Multidrug-resistant, *Klebsiella pneumoniae*, Carbapenemase, Oxacillinase, Fomites

**DOI:** <https://doi.org/10.21203/rs.3.rs-42624/v3>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

## Objective

The acquisition of carbapenemase-producing organisms in healthcare settings is a significant threat and has dire implications for public health. Previous reports regarding carbapenemase-producing *Enterobacteriaceae* from fomites are limited. This study aimed to analyse the antimicrobial resistance patterns and prevalence of carbapenemase-producing *Klebsiella pneumoniae* in the ward environments of a tertiary health institution in Nigeria.

## Results

One hundred and forty-two bacteria were isolated from 534 fomites in the hospital wards, and out of these, 15(10.6%) were *K. pneumoniae*. Therefore, the prevalence of *K. pneumoniae* in all the samples was 15/534(2.8%), while that of carbapenemase-producing *K. pneumoniae* was 8/534(1.5%). Multi-drug resistance was detected in 15/15(100%) of the *K. pneumoniae* isolated. All the *K. pneumoniae* isolates were resistant to ampicillin, trimethoprim-sulfamethoxazole, cefuroxime, and tetracycline. Although 8/15(53.3%) of the isolates were confirmed positive for carbapenemase production using the modified Hodge test, no *Klebsiella pneumoniae* carbapenemase gene (*bla<sub>KPC</sub>*) was detected. The most frequent sites that harboured carbapenem-resistant *K. pneumoniae* were the beds 6/15(40%). Hence, the prevalence of carbapenemase-producing *K. pneumoniae* fomite colonisation in the NAUTH ward environment was low.

## Introduction

*Klebsiella pneumoniae* are Gram-negative, non-motile, encapsulated bacilli belonging to the family of bacteria called the *Enterobacteriaceae* [1]. They are considered the second most common cause of healthcare-associated sepsis, remaining for long periods in hospital environments and equipment. They may be spread to patients by contact with these environmental surfaces [2, 3]. They develop resistance by various mechanisms, but by far, the most troublesome of these are the carbapenemases which make the organisms resistant to almost all forms of antibiotics [4, 5]. These enzymes are also resistant to the carbapenems which have been considered as agents of last resort in the treatment of infections caused by MDR Gram-negative bacilli [4, 5].

The burden of antimicrobial resistance (AMR) in developing countries has increased remarkably in recent years [6, 7]. In a 2017 review of AMR in Africa, only about 60% of the countries had available data on AMR. There was a strikingly high median resistance (MR) rate for the *Enterobacteriaceae* to ampicillin (MR= 88.1%) [6]. Resistance was however uncommon for the carbapenem group of antibiotics. In particular, 34.2% of the *Klebsiella spp.* were resistant to ceftriaxone, while 46.7% exhibited resistance to cefotaxime. This observation suggested a high-level extended-spectrum beta-lactamase (ESBL) production. However, the median resistance rate for *K. pneumoniae* against imipenem, a carbapenem

was 3.0% [6]. In another survey involving Africa and Asia, high resistance rates were also observed for ampicillin (67.2%) and ceftriaxone (25.9%) [7].

The most frequently detected carbapenemases include class A- *Klebsiella pneumoniae* carbapenemase (KPC) types), class B- metallo- $\beta$ -lactamases (MBLs) viz Verona integron-encoded metallo- $\beta$ -lactamase (VIM) and NewDelhi metallo- $\beta$ -lactamase (NDM) types, and class D- oxacillinases (OXA-48-like enzymes) [8]. Furthermore, KPCs are major causes of nosocomial outbreaks [9-11].

Several studies done previously on carbapenemase detection focused more on isolates from clinical specimens of patients. Still, limited information is available in the literature on the prevalence of carbapenemase-producing *K. pneumoniae* in the hospital environment. One environmental study worthy of note was that in which the presence of carbapenemase-producing *K. pneumoniae* was determined in environmental sites of Intensive Care Units (ICUs) in Cairo, Egypt [12]. This study, therefore, aimed at assessing the occurrence of carbapenemase-producing *K. pneumoniae* in the ward environments of a tertiary health institution in Nigeria.

## Methods

### Study Population

One hundred and forty-two bacterial isolates were isolated from 534 environmental specimens obtained in the wards of NAUTH, Nnewi, a major referral centre serving individuals from most parts of South-East, Nigeria. The bacteria were collected from January to June 2018. The specimens included swabs collected from; patients beds, bedside tables, bedside cupboards, trolleys, sphygmomanometers, water taps, antiseptics, disinfectants, hand wash solutions, hand sanitisers, forceps, wheelchairs, kidney dishes, door handles, drip stands, drug mortars, methylated spirits, suction tubes, nurses desks, doctors desks and pulse oximeters.

### Bacterial Isolation

Duplicate swabs were collected by rolling moistened sterile swab sticks over the sites mentioned above for about 5 seconds. These swabs were sent to the laboratory immediately after collection and cultured on chocolate and Mac Conkey agar (Oxoid, UK) and incubated at 35–37°C for 24 hours [10, 12]. The isolates were Gram-stained, and the Gram-negative rods were subjected to confirmatory identification of *K. pneumoniae* using the Microbact™ Gram-negative bacteria identification kit (Oxoid, UK) [10].

### Antimicrobial Susceptibility testing

The Modified Kirby-Bauer antimicrobial susceptibility testing technique was performed on all isolates confirmed as *K. pneumoniae* [13, 14]. A lawn of each bacterial inoculum equivalent to  $1.5 \times 10^8$  CFU/ml, was made on the surface of a Mueller-Hinton agar (Oxoid, UK) plate using a sterile swab stick and left to

dry for 3-5 minutes. Antibiotics were then placed on the lawn, and the plates incubated aerobically at 35-37°C for 16-18 hours. The zones of growth inhibition around each antibiotic disc were measured and reported based on the guidelines of the CLSI [14].

### **Screening for suspected carbapenemase production**

This involved placing 10µg carbapenem discs viz meropenem and ertapenem (Oxoid, UK) on the surface of Mueller Hinton agar (Oxoid, UK) plates inoculated with each isolate. Following incubation for 16-18 hours at 35-37°C, zones of growth inhibition around each antibiotic were read off.

*K. pneumoniae* isolates that showed a zone of inhibition  $\leq$  22mm in diameter for meropenem or  $\leq$  21mm for ertapenem were considered as suspected carbapenemase producers and were subjected to phenotypic confirmation by the modified Hodges test (MHT) [11, 14].

### **Phenotypic confirmation of carbapenemase production (MHT)**

In this method, a suspension of *E. coli* ATCC 25922 equivalent to 0.5 McFarland turbidity standard was prepared. The *E. coli* suspension was then diluted 1:10 by adding 0.5 ml of the *E. coli* suspension to 4.5 ml of saline. A lawn of the 1:10 dilution of *E. coli* ATCC 25922 was evenly streaked onto Mueller Hinton agar plates using sterile cotton swabs and then allowed to dry for 3-5 minutes. One disc of meropenem (10µg), was placed on the centre surface of the MHA plate. In a straight line, using a sterilised wire loop, the test organisms were streaked from the edge of each Meropenem disc to the edge of the plate. The plates were incubated at 37°C for 24 hours. After incubation, they were examined for a cloverleaf type indentation at the intersection of the test organism and *E. coli* ATCC 25922 within the zone of inhibition of the meropenem disc as described by the CLSI.[14] *K. pneumoniae* ATCC 1705 and *K. pneumoniae* ATCC 1706 were used as positive and negative controls [14].

### **Molecular Detection of bla<sub>KPC</sub>**

Bacteria DNA from the *K. pneumoniae* isolates was extracted using a previously described boiling method for DNA extraction with slight modifications [15, 16]. The extracted DNA was quantified and tested for purity using the NanoDrop® ND-1000 spectrophotometer (Additional file 1: Table S1). The bla<sub>KPC</sub> gene was detected using a conventional PCR reaction that was based on the protocols and primer sequences previously published by Shanmugam *et al.*, with slight modifications [17]. (Additional file 2: Table S2).

The PCR conditions for bla<sub>KPC</sub> detection were as follows: initial denaturation at 94°C for 3 minutes, followed by 30 cycles of denaturation at 94°C for 1 minute, annealing at 60°C for 1 minute, extension at 72°C for 1 minute, then final extension at 72° C for 5 minutes. The products were then resolved at 130V for 25 minutes on 1.5% agarose gel stained with 0.5µg/ml ethidium bromide solution (Nippon Genetics, Europe GmbH) in an electrophoresis tank containing one mMol Tris-Borate EDTA (TBE) buffer. The gels

were observed under UV gel Transilluminator (UV DOC, England) at 280nm, and the band pattern observed.

## Data Analysis

Statistical analysis was done using STATA version 13 (Stata Corp LP, Texas, USA). Prevalence was determined using frequency distribution tables.

## Results

One hundred and forty-two bacteria were isolated from 534 fomites in the hospital wards, and out of these, 15(10.6%) were *K. pneumoniae*. Thus, the prevalence of *K. pneumoniae* in the entire sample population was 15/534(2.8%). (Additional file 3: Table S3).

The male surgical ward had the highest proportion of *K. pneumoniae* isolates 5(33.3%), followed by the male and female medical wards which had 3(20%) each. (Additional file 4: Table S4).

The highest resistance pattern (100% resistant) was observed against ampicillin, trimethoprim-sulphamethoxazole, cefuroxime and tetracycline. In comparison, the least amount of resistance was seen in the carbapenem class of antibiotics, including imipenem (26.7%), meropenem (40.0%) and ertapenem (46.7%). (Table 1) (Additional file 5: Table S5).

All the *K. pneumoniae* isolates were at least multi-drug resistant, and out of the 15 isolates, 8 (53.3%) were confirmed phenotypically as carbapenemase producers. The largest proportion of these phenotypic carbapenemase producers were seen in *K. pneumoniae* isolated from bed surfaces 4 (26.7%). (Table 2) (Additional file 6: Figure S1).

The bla<sub>KPC</sub> gene was undetected in the *K. pneumoniae* isolates (Figure 1).

## Discussion

*K. pneumoniae* is a frequent cause of infections, accounting for up to 10% of all nosocomial infections [18]. Carbapenems are the drugs of choice for the treatment of infections caused by drug-resistant *Enterobacteriaceae* [19]. Unfortunately, rising bacterial resistance to carbapenems has been well documented [20]. Previous studies have shown that *K. pneumoniae* strains of environmental origin are similar to those of clinical origin in terms of biochemical patterns, virulence, and pathogenicity. However, clinical *K. pneumoniae* have been observed to be significantly more resistant to antibiotics when compared with environmental *K. pneumoniae* [21].

*K. pneumoniae* was isolated from 15/534 (2.8%) of the study population. A slightly lower rate was obtained in environmental isolates of *K. pneumoniae* in an Egyptian hospital, where 4/100 (0.04%) of the study population was found to harbour *K. pneumoniae* [22].

Out of 142 isolated organisms, 15 (10.6%) were confirmed to be *K. pneumoniae* with 8(53%) of these observed to be producing carbapenemases. A higher rate was observed in the northern region of Brazil, where 25/25 (100%) of the *K. pneumoniae* isolates were confirmed as carbapenemase producers [23], but much lower values were observed for clinical isolates of *K. pneumoniae* in a Chinese study 4/153 (2.6%) [24]. In Kano, Nigeria, a low prevalence of carbapenemase-producing *K. pneumoniae* was also observed 6/73 (8.2%) [11]. The varying prevalence of carbapenemase production could be a result of different selection pressures from different antibiotic prescribing preferences in other countries. These inconsistent observations were highlighted in a statement by Oduyebo *et al.*, that carbapenemase production among the *Enterobacteriaceae* has been widely reported with prevalence ranges between 2.8% and 53.6% [10].

The most frequent site of isolation was in beds 6/15 (40%), followed by bedside cupboards 4/15 (26.7%), and then bedside tables 2/15 (13.3%). This finding was similar to that observed in Egypt, where the *K. pneumoniae* isolated from several ICUs were found more in beds, bedside tables, suction tubes, and ventilator tubes [12]. However, no *K. pneumoniae* was isolated from the ICU in this study. This variation in the detection of the organisms from the ICUs of the different hospitals could be attributed to the maintenance of strict infection control measures in the ICU of NAUTH, Nnewi.

The antibiotic susceptibility patterns of the *K. pneumoniae* isolates revealed that the organisms had maximum resistance (100%) to Ampicillin, Sulfamethoxazole-Trimethoprim, Cefuroxime, and Tetracycline, but were most susceptible to the Carbapenem class of antibiotics, in which imipenem showed the most sensitivity (73.3%). Contrasting findings were observed in an Egyptian study which revealed 100% resistance to meropenem [12]. The reduced rates of resistance to the carbapenems in this study could be attributed to the limited use of carbapenems due to the high cost of purchase of these antibiotics in the country.

None of the 15 isolates of *K. pneumoniae* produced bla<sub>KPC</sub>. Although this was similar to findings observed in previous Nigerian studies which dealt with clinical isolates of *K. pneumoniae* [10, 25], contrasting observations were seen in Maiduguri, Nigeria (6.5%) [11]. A significantly different finding was also observed in a Brazilian study that revealed that 100% of the *K. pneumoniae* isolates carried the bla<sub>KPC</sub> gene [23]. The contrasting rates may be due to long term high use of carbapenems in Brazil, which in Nigeria, have only recently been introduced.

The *K. pneumoniae* isolates were phenotypically positive for carbapenemase production on modified Hodge test but were negative for bla<sub>KPC</sub> gene on PCR. This could be because these isolates harboured other carbapenemase-producing genes (including bla<sub>NDM</sub>, bla<sub>VIM</sub>, bla<sub>OXA-48</sub> etc.), which were not searched for in this study.

## Conclusion

Although the prevalence of carbapenemase production in the *K. pneumoniae* isolates was high, the rate of colonisation of fomites with these pathogens in the NAUTH ward environment was still relatively low.

# Limitations

All the genes responsible for carbapenemase production were not searched for. Although this limitation did not adversely affect the aim of this study, which was to determine carbapenemase production in the organisms, it would have been more accurate to detect all the genes responsible for its production. The phenotypic detection method (MHT) used in this study helped to curb this limitation. Larger sample size may also have helped to improve the accuracy of the survey.

# Abbreviations

MHT: Modified Hodges Test

NAUTH: Nnamdi Azikiwe University Teaching Hospital

KPC: *Klebsiella pneumoniae* Carbapenemase

MBL: Metallo- $\beta$ -lactamase

VIM: Verona integron-encoded metallo- $\beta$ -lactamase

NDM: New Delhi metallo- $\beta$ -lactamase

OXA-48: Oxacillinases-48

ICU: Intensive Care Unit

MDR: Multi-drug resistant

ESBL: Extended Spectrum Beta-lactamase

PCR: Polymerase Chain Reaction

# Declarations

## Ethics approval and consent to participate

Ethical approval was obtained from the Research and Ethics Committee of Nnamdi Azikiwe University Teaching Hospital (NAUTH), Nnewi, with reference number NAUTH/CS/66/VOL.9/143/2016/11. Also, all isolates used in this study were obtained from inanimate materials in the wards of NAUTH, Nnewi. Hence permission/consent to participate in the study was given by the Chairman Medical Advisory Committee on behalf of the NAUTH Board of Management, with reference number NAUTH/CS/152/VOL. 2/224.

## Consent for publication

Not applicable.

# Availability of data and materials

The necessary data generated or analysed during this study are included in this article (and its supplementary information files).

## Competing interests

The authors declare that they have no competing interests.

## Funding

This work and the subsequent article did not receive any form of financial support in the form of funding, grants or supplies.

## Author's contributions

AIN and ACN designed the experiments and performed the literature search. All authors made conceptual contributions. AIN, AIM, ECJ, MNP, and UNG performed laboratory experiments, as well as data acquisition. CCG and AIN analysed the data. AIN wrote the manuscript. USN, UCF, and ACN edited and reviewed the manuscript. All authors read and approved the final version of the document. AIN was the project leader, while ACN was the project supervisor.

## Acknowledgements

Special appreciations go to Prof. Tاتفeng Mirabeu (Coordinator, Molecular Biology Laboratory, Niger Delta University, Bayelsa, for his tutelage and assistance in the molecular analysis aspects of the work. We also acknowledge the technical assistance of Dr. Ikemefuna Onyeyili, as well as our research assistants; Cynthia, Favour, Mmesoma, and Matron Ezeji.

# Author information

## Affiliations

1. Department of Medical Microbiology/Parasitology, Faculty of Medicine, Nnamdi Azikiwe University, Awka.
2. Department of Community Medicine, Faculty of Medicine, Nnamdi Azikiwe University, Nnewi Campus.
3. Department of Nursing Sciences, School of Nursing, Nnamdi Azikiwe University Teaching Hospital, Nnewi.
4. Department of Medical Microbiology/Parasitology, Nnamdi Azikiwe University Teaching Hospital, Nnewi.

5. Department of Applied Microbiology and Brewing, Nnamdi Azikiwe University, Awka.

Aghanya IN<sup>1</sup>, Akujobi CN<sup>1</sup>, Ushie SN<sup>1</sup>, Ubajaka CF<sup>2</sup>, Ajuba IM<sup>1,3</sup>, Ezeama CJ<sup>1</sup>, Maduekwe NP<sup>4</sup>, Uzoewulu NG<sup>1</sup>, Chigbo CG<sup>5</sup>.

## References

1. Parisi SG, Bartolini A, Santacatterina E, Castellani E, Ghirardo R, Berto A *et al.* Prevalence of *Klebsiella pneumoniae* strains producing carbapenemases and increase of resistance to colistin in an Italian teaching hospital from January 2012 To December 2014. *Bio Med Central Infectious Diseases*. 2015;**15**:244.
2. Jones RN. Microbial Etiologies of Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia. *Clinical Infectious Diseases*. 2010;**51**(S1):S81-S87.
3. Peleg AY, Hopper DC. Hospital-Acquired Infections Due to Gram-negative Bacteria. *New England Journal of Medicine*. 2010;**362**:1804-1813.
4. Chen LF, Anderson DJ, Paterson DL. Overview of the epidemiology and the threat of *Klebsiella pneumoniae* carbapenemases (KPC) resistance. *Infection and Drug Resistance*. 2012;**5**:133-141.
5. Zhang X, Chen D, Xu G, Huang W, Wang X. Molecular epidemiology and drug resistant mechanism in carbapenem-resistant *Klebsiella pneumoniae* isolated from pediatric patients in Shanghai, China. *PLoS ONE*. 2018;**13**(3):e0194000.
6. Tadesse BT, Ashley EA, Ongarello S, et al. Antimicrobial resistance in Africa: a systematic review. *BMC Infect Dis*. 2017;**17**(1):616.
7. Belete MA, Saravanan M. A Systematic Review on Drug Resistant Urinary Tract Infection Among Pregnant Women in Developing Countries in Africa and Asia; 2005–2016. *Infect Drug Resist*. 2020;**13**:1465-1477
8. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. *Emerging Infectious Diseases*. 2011;**17**:1791–1798.
9. Ilaria F, Biasolo M, Bartolini A, Cavallaro A, Richter S, Palù G. Rapid detection of blaVIM-1–37 and blaKPC1/2–12 alleles from clinical samples by multiplex PCR-based assays. *International Journal of Antimicrobial Agents*. 2013;**42**(1):68–71.
10. Oduyebo OO, Falayi OM, Oshun P, Ettu AO. Phenotypic determination of carbapenemase producing enterobacteriaceae isolates from clinical specimens at a tertiary hospital in Lagos, Nigeria. *Nigerian Postgraduate Medical Journal*. 2015;**22**:223-227.
11. Mohammed Y, Zailani SB, Onipede AO. Characterisation of KPC, NDM and VIM Type Carbapenem Resistance Enterobacteriaceae from North Eastern, Nigeria. *Journal of Biosciences and Medicines*. 2015;**3**:100-107.
12. Abdallah S, Zaki S, Hafez S, Moustafa E. Prevalence rate of *Klebsiella pneumoniae* in the intensive care unit: epidemiology and molecular characteristics. *Journal of Biological Research - Bollettino*

*Della Società Italiana Di Biologia Sperimentale*, 2018;**91**(1).

13. Yusuf I, Magashi AM, Firdausi FS, Sharif AA, Getso MI, Bala JA, Aliyu IA. Phenotypic Detection of Carbapenemases in Members of Enterobacteriaceae in Kano, Nigeria. *International Journal of Science and Technology*. 2012;**2**(11):802-806.
14. Performance Standards for Antimicrobial Susceptibility Testing. Twenty- Seventh informational supplement. M100-S27. Clinical and Laboratory Standards Institute. Wayne, PA. 2017;**37**(1).
15. **De Medici D, Croci L, Delibato E, Di Pasquale S, Filetici E, Toti L.** Evaluation of DNA extraction methods for use in combination with SYBR green I real-time PCR to detect *Salmonella enterica* serotype enteritidis in poultry. *Environ. Microbiol.* 2003;**69**:3456-3461.
16. Queipo-Ortuño MI, De Dios Colmenero J, Macias M, Bravo MJ, Morata P. Preparation of Bacterial DNA Template by Boiling and Effect of Immunoglobulin G as an Inhibitor in Real-Time PCR for Serum Samples from Patients with Brucellosis. *Clinical and Vaccine Immunology*. 2008;**15**(2):293-296.
17. Shanmugam P, Meenakshisundaram J, Jayaraman P. blaKPC gene Detection in Clinical Isolates of Carbapenem Resistant Enterobacteriaceae in a Tertiary Care Hospital. *Journal of Clinical Diagnostics and Research*. 2013;**7**(12):2736–2738.
18. Gorrie CL, Mirceta M, Wick RR, Edwards DJ, Thomson NR, Strugnell RA, Pratt NF, Garlick JS, Watson KM, Pilcher DV, McGloughlin SA, Spelman DW, Jenney AWJ, Holt KE. (2017). Gastrointestinal Carriage Is a Major Reservoir of *Klebsiella pneumoniae* Infection in Intensive Care Patients. *Clin Infect Dis*. **65**(2):208-215.
19. Okoche D, Asiimwe BB, Katabazi FA, Kato L, Najjuka CF. (2015). Prevalence and Characterisation of Carbapenem-Resistant Enterobacteriaceae Isolated from Mulago National Referral Hospital, Uganda. *Zhang Q, ed. PLoS ONE*. **10**(8):e0135745.
20. Codjoe, F. S., & Donkor, E. S. (2017). Carbapenem Resistance: A Review. *Medical sciences (Basel, Switzerland)*. **6**(1), 1.
21. Struve C, Krogfelt KA. (2004). Pathogenic potential of environmental *Klebsiella pneumoniae* *Environmental microbiology*. **6**:584-590.
22. Mohamed ER, Aly SA, Halby HM, Ahmed SH, Zakaria AM, El-Asheer OM. (2017). Epidemiological typing of multidrug-resistant *Klebsiella pneumoniae*, which causes paediatric ventilator-associated pneumonia in Egypt. *Journal of Medical Microbiology*. **66**:628–634.
23. Ferreira RL, Da Silva BC, Rezende GS, Nakamura-Silva R, Pitondo-Silva A, Campanini EB, Brito MCA, Da Silva EML, Freire C, Da Cunha AF, Pranchevicius MD. (2019). High Prevalence of Multidrug-Resistant *Klebsiella pneumoniae* Harboring Several Virulence and  $\beta$ -Lactamase Encoding Genes in a Brazilian Intensive Care Unit. *Frontiers in Microbiology*. **9**(3389):1-15.
24. Du J, Li P, Liu H, Lü D, Liang H, Dou Y. (2014). Phenotypic and Molecular Characterisation of Multidrug Resistant *Klebsiella pneumoniae* Isolated from a University Teaching Hospital, China. *PLoS ONE*. **9**(4): e95181.

25. Onukwube CC, Agbakoba NR, Egwuatu CC, Aghanya IN. (2017). Detection of Carbapenem-Resistant *Klebsiella pneumoniae* Isolates from Clinical Specimens in Nnamdi Azikiwe University Teaching Hospital, Nnewi. *International Journal of current Research and Review*. 9(10):44-48.

## Tables

**Table 1: Antibiogram of the *Klebsiella pneumoniae* Isolates**

Antibiotic Class	Antibiotic	Disk content	Susceptible	Resistant
			n(%)	n(%)
Penicillins	Ampicillin	10µg	0(0.0)	15(100.0)
β-lactam/β-lactamase Inhibitor	Amoxicillin-clavulanate	20/10µg	1(6.7)	14(93.3)
Folate Inhibitor	Trimethoprim-sulfamethoxazole	1.25/23.75µg	0(0.0)	15(100.0)
Cephalosporins	2 <sup>nd</sup> gen: Cefuroxime	30µg	0(0.0)	15(100.0)
	3 <sup>rd</sup> gen: Cefotaxime	30µg	4(26.7)	11(73.3)
	3 <sup>rd</sup> gen: Ceftazidime	30µg	6(40.0)	9(60.0)
	4 <sup>th</sup> gen: Cefepime	30µg	7(46.7)	8(53.3)
	Aminoglycosides	Gentamicin	30µg	5(33.3)
Carbapenems	Ertapenem	10µg	8(53.3)	7(46.7)
	Meropenem	10µg	9(60.0)	6(40.0)
	Imipenem	10µg	11(73.3)	4(26.7)
Quinolones	Ciprofloxacin	5µg	6(40.0)	9(60.0)
Tetracycline	Tetracycline	30µg	0(0.0)	15(100.0)

Key: µg= microgram, n= number, %= percentage, gen= generation

**Table 2: Distribution of carbapenemase production in the *Klebsiella pneumoniae* isolated from the sample sources**

Sample Source (n)	MDR Isolates, n(%)	Carbapenemase Production	
		Yes, n(%)	No, n(%)
<b>Beds (6)</b>	6(40.0)	4(26.7)	2(13.3)
<b>Bed Tables (2)</b>	2(13.3)	1(6.7)	1(6.7)
<b>Chlorhexidine (1)</b>	1(6.7)	1(6.7)	0(0.0)
<b>Cupboards (4)</b>	4(26.7)	2(13.3)	2(13.3)
<b>Hand Wash (1)</b>	1(6.7)	0(0.0)	1(6.7)
<b>Forceps (1)</b>	1(6.7)	0(0.0)	1(6.7)
<b>Total (15)</b>	<b>15(100.0)</b>	<b>8(53.3)</b>	<b>7(46.7)</b>

Key: n= number, %= percentage, MDR= multi-drug resistant

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [TableS1.docx](#)
- [TableS3.docx](#)